Benner M F, Willemze R
Department of Dermatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
Br J Dermatol. 2008 Nov;159(5):1148-51. doi: 10.1111/j.1365-2133.2008.08812.x. Epub 2008 Sep 6.
According to criteria of the World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas a diagnosis of primary cutaneous CD30-positive anaplastic large cell lymphoma (C-ALCL) should be made only when systemic localizations have been excluded by adequate staging procedures, including a bone marrow biopsy. It has recently been questioned whether or not bone marrow examination should be performed routinely in indolent cutaneous lymphomas such as C-ALCL. Studies addressing this issue have never been performed.
To determine the incidence of bone marrow involvement in patients with an ALCL first presenting in the skin to find out if the current policy to advise bone marrow examination should be maintained or whether a bone marrow biopsy should be performed only in selected cases.
All patients presenting with skin lesions with histological and immunophenotypical features of an ALCL were retrieved from the database of the Dutch Cutaneous Lymphoma Group. Patients with a history of systemic ALCL and patients without bone marrow examination were excluded from the study. The final study group included 107 patients with an ALCL first presenting in the skin, who had been staged completely.
Staging procedures showed the presence of extracutaneous disease in 20 patients, but bone marrow involvement was not detected in any of the 107 patients. Moreover, only one patient developed bone marrow involvement during follow up (median follow-up period 69 months).
Bone marrow examination has limited value in the staging of patients with an ALCL first presenting in the skin, and should be performed only in selected cases.
根据世界卫生组织-欧洲癌症研究与治疗组织皮肤淋巴瘤分类标准,仅当通过包括骨髓活检在内的适当分期程序排除了全身受累时,才能做出原发性皮肤CD30阳性间变性大细胞淋巴瘤(C-ALCL)的诊断。最近有人质疑,对于诸如C-ALCL等惰性皮肤淋巴瘤患者,是否应常规进行骨髓检查。尚未有针对此问题的研究。
确定初发于皮肤的间变性大细胞淋巴瘤(ALCL)患者的骨髓受累发生率,以了解是否应维持目前建议进行骨髓检查的政策,还是仅在特定病例中进行骨髓活检。
从荷兰皮肤淋巴瘤研究组的数据库中检索所有具有ALCL组织学和免疫表型特征的皮肤病变患者。有全身性ALCL病史的患者和未进行骨髓检查的患者被排除在研究之外。最终研究组包括107例初发于皮肤的ALCL患者,这些患者均已完成分期。
分期检查显示20例患者存在皮肤外病变,但107例患者中均未检测到骨髓受累。此外,随访期间仅有1例患者出现骨髓受累(中位随访期69个月)。
骨髓检查在初发于皮肤的ALCL患者分期中的价值有限,仅应在特定病例中进行。